Martin Naley recently founded a company called OctX. It's is an oncology trial information exchange, providing accurate, complete, and up-to-date information about clinical trials, designed to help everyone who is helping patients find cancer trial options. Before founding OctX, Martin was Program Lead, Clinical Trials Acceleration at Biden Cancer Initiative, where he developed the Oncology Clinical Trial Information Commons, an alliance to overcome systemic barriers affecting clinical trial enrollment. Martin continues to lead that alliance as a consultant at Cancer Commons. Martin has created and led technology-based businesses in the fields of digital health, clinical trial matching, real-world data, and precision medicine. Through his entrepreneurial experience, he has developed deep knowledge about health data access, technology platforms, and the interests of patients, providers, and drug developers. Martin began his career with 15 years in management and executive positions at Life Technologies, a leading provider of scientific tools powering personalized medicine.
Precision medicine has incredible promise for patients. Enormous amounts of money and time are invested in developing technologies and targeted therapies. Genomics, proteomics, phosphorylation assays, RNA expression, organoid growth, and testing, and even delicate mass measurement of liquid cancer cells are explored. This innovation must be focused to maximize the benefit to the most important participants in our healthcare system, the patient. This track is about putting patient needs first, and understanding and accessing the latest (cancer) treatment options.